Factors Impacting CML Treatment Selection

Video

Neal Dave, PharmD, explores how the generation of the tyrosine kinase inhibitors (TKIs) play a role in treatment selection.

Neal Dave, PharmD: If you have 2 choices, and you have the same clinical outcome or benefit, and there’s essentially no difference, then cost is definitely taken into account—not just the cost of therapy but also the cost to the patient and to the health care system. If there’s any additional cost to adverse effect management, all that is taken into account. You want the lowest-cost therapy, but you don’t want to sacrifice quality of care. We’re heavily into value-based care, and almost every decision that’s made is central to 1 clinical outcome.

The first- and second-generation tyrosine kinase inhibitors are all very similar in their responses. When you look at overall survival, particularly progression-free survival, there are studies that show that 1 is better than the other or had a little faster response. There are some differences between first- and second-generation tyrosine kinase inhibitors.

The first-generation 1 is less expensive. It still has a great response rate. The others are a little more costly compared with the first-generation. In this class, you’re specifically looking at the adverse effects of drug interactions and any comorbid conditions that the patient may have—whether 1 drug is better than the other. It’s very selective based on the patient’s history and what the patient is presenting with.

Transcript edited for clarity.

Related Videos
Video 2 - "Achieving Post-Discharge Success: Goals in Hepatic Encephalopathy Care"
Video 1 - "Identifying and Screening for Hepatic Encephalopathy Risk Factors"
Video 15 - "Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM  "
Video 12 - "Pharmacist Role in Addressing Operational Challenges of  Bispecifics in MM"
Video 12 - "Pharmacist Role in Addressing Operational Challenges of  Bispecifics in MM"
Video 12 - "Pharmacist Role in Addressing Operational Challenges of  Bispecifics in MM"
Video 11 - "Complying with REMS Training and Documentation Requirements"
Video 09 - "Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma"
Video 09 - "Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma"
Video 8 - "Final Thoughts on Operationalization of Bispecific Antibodies for Multiple Myeloma"
© 2024 MJH Life Sciences

All rights reserved.